This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apple, DuPont: New Targets, Estimates

Stocks in this article: AAPL DD

Also see: ADP, Amdocs, Cree: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Apple (AAPL) estimates were increased through 2012 at Needham. Company should see better iPad and Mac shipments, Needham said. Maintain $450 price target.

Cytec (CYT) estimates, target were cut through 2012 at Jefferies. Company could face further weakness in its coatings business, Jefferies said. Buy rating and new $64 price target.

DuPont (DD) estimates were increased at Jefferies through 2012. Company is realizing higher TiO2 prices, Jefferies said. Buy rating and $64 price target.

Forest Laboratories (FRX) estimates, target were increased at Credit Suisse. Shares now seen reaching $46, and estimates were also increased on M&A interest by larger peers. Credit Suisse said.

Garmin (GRMN) estimates, target were lowered at Goldman Sachs. Shares now seen reaching $30. Estimates also cut, following the warning from TomTom, Goldman said. Neutral rating.

Grainger (GWW) estimates, target were raised at UBS. Shares now seen reaching $156. Estimates also increased on good opportunities on margins, UBS said. Neutral rating.

Huntsman (HUN) estimates, target were raised at Jefferies. Shares now seen reaching $26. Estimates also increased, given higher TiO2 prices, Jefferies said. Buy rating.

Johnson Controls (JCI) estimates, target were increased at Piper Jaffray. Shares now seen reaching $51. Estimates were also increased on stronger-than-expected start-stop battery demand, Piper Jaffray said. Overweight rating.

Jacobs Engineering (JEC) estimates, target cut at UBS. Shares now seen reaching $45. Estimates also lowered, as macro pressures remain UBS said. Neutral rating.

Marathon Oil (MRO) estimates were boosted through 2013 at UBS. Improved refining margin outlook, UBS said. Maintain Buy rating and $60 price target.

Teva Pharmaceutical (TEVA) estimates were lowered through 2012 at Jefferies. Stock is down 16% over the past year, even though the company has made positive strategic moves, Jefferies said. Hold rating and $53 price target.

End of report.

This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs